SAMβA, βIIPKC_624-632 peptide

SAMβA, βIIPKC_624-632 peptide

• COA/MS/HPLC Report
• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

H-RNAENFDRF-NH2

H-Arg-Asn-Ala-Glu-Asn-Phe-Asp-Arg-Phe-NH2

9

95.2%

C₅₀H₇₄N₁₈O₁₅

1167.23

Synthetic

Powder

SAMβA(βIIPKC_624-632) is a 9-amino-acid peptide(sequence: RNAENFDRF) which is a selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats. SAMβA may be a potential treatment for patients with heart failure. Treatment of cultured neonatal cardiac myocytes with SAMβA prevented mitochondrial fragmentation triggered by angiotensin II. SAMβA reduced the excessive association of βIIPKC with Mfn1 induced by angiotensin II in cardiac myocytes, as measured by co-immunoprecipitation. The treatment of cardiac neonatal myocytes with SAMβA had a better effect in protecting against H2O2-induced metabolic dysfunction when compared to the global βIIPKC inhibitor, βIIV5-3.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Ferreira, J. C. B., Campos, J. C., Qvit, N., Qi, X., Bozi, L. H. M., Bechara, L. R. G., u2026 Mochly-Rosen, D. (2019). A selective inhibitor of mitofusin 1-u03b2IIPKC association improves heart failure outcome in rats. Nature Communications, 10(1). https://doi.org/10.1038/s41467-018-08276-6

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.